TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2255932

Group type: EXPERIMENTAL
Intervention: Buprenorphine (2.5 and 5 micrograms/kilogram body weight)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pethidine (0.8 milligram/kilogram)
Number of subjects: 0
Study: 7378240

Group type: EXPERIMENTAL
Intervention: pancuronium
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: tubocuraine
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: alcuronium
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: fazadinium
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: suxamethonium
Number of subjects: 50
Study: 31551228

Group type: EXPERIMENTAL
Intervention: Dexamethasone combined with ambroxol hydrochloride
Number of subjects: 86

Group type: COMPARATOR
Intervention: Ambroxol hydrochloride
Number of subjects: 86
Study: 28224234

Group type: EXPERIMENTAL
Intervention: 1-day nasogastric tube decompression (NGT group)
Number of subjects: 233

Group type: COMPARATOR
Intervention: no nasogastric tube decompression (no-NGT group)
Number of subjects: 233
Study: 26571827

Group type: EXPERIMENTAL
Intervention: Fast neutrons 6.3 MeV combined with neutron-photon therapy
Number of subjects: 0
Study: 23897424

Group type: EXPERIMENTAL
Intervention: 15-μg epinephrine test dose
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Threshold increase of 20 bpm
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Threshold increase of 10 bpm or increase in systolic blood pressure of 15 mm Hg or greater
Number of subjects: 24
Study: 21768280

Group type: EXPERIMENTAL
Intervention: Purified lipopolysaccharide (LPS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LPS homologous to that expressed on the bactericidal test strain
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Heterologous LPS
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Convalescent-phase serum with CMP-NANA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Highly sialylated LPS
Number of subjects: 0
Study: 19555710

Group type: EXPERIMENTAL
Intervention: Multi-factorial lifestyle intervention (including low intensity alcohol intervention)
Number of subjects: 9415

Group type: EXPERIMENTAL
Intervention: Multi-factorial lifestyle intervention
Number of subjects: 9415

Group type: COMPARATOR
Intervention: Control group (questionnaires)
Number of subjects: 9415
Study: 16467444

Group type: EXPERIMENTAL
Intervention: Cyclosporine (CsA)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 60
Study: 12942477

Group type: EXPERIMENTAL
Intervention: Graft inflow modification (GIM) by splenic artery ligation in G2, n = 13
Number of subjects: 24

Group type: COMPARATOR
Intervention: No graft inflow modification in G1, n = 11
Number of subjects: 24
Study: 11068838

Group type: EXPERIMENTAL
Intervention: lodixanol
Number of subjects: 160

Group type: COMPARATOR
Intervention: lopromide
Number of subjects: 160
Study: 9357205

Group type: COMPARATOR
Intervention: Metered Dose Inhaler with Spacer (Group II)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Jet Nebulizer (Group I)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups (Group I and Group II)
Number of subjects: 60
Study: 8442971

Group type: EXPERIMENTAL
Intervention: midazolam 0.6 mg/kg
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: diazepam 0.3 mg/kg
Number of subjects: 75

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 75
Study: 2943613

Group type: EXPERIMENTAL
Intervention: Water-based benzoyl peroxide (Basiron)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Alcohol-based benzoyl peroxide (Panoxyl)
Number of subjects: 48
Study: 31278470

Group type: EXPERIMENTAL
Intervention: Intracutaneous sterile water injection (ISWI)
Number of subjects: 524

Group type: COMPARATOR
Intervention: Diclofenac sodium injection
Number of subjects: 524
Study: 29435760

Group type: EXPERIMENTAL
Intervention: Self‐Paced (S‐P) training
Number of subjects: 24

Group type: COMPARATOR
Intervention: Standardised (STND) training
Number of subjects: 24
Study: 27606699

Group type: EXPERIMENTAL
Intervention: Prolonged Exposure (PE)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Virtual Reality Exposure (VRE)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Minimal Attention Waitlist (WL)
Number of subjects: 162
Study: 24486592

Group type: EXPERIMENTAL
Intervention: Topical application of 10% w/w freeze-dried black raspberry gel (BRB), 0.5 g × q.i.d., for 12 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo gel (identical formulation devoid of BRB)
Number of subjects: 40
Study: 22395584

Group type: EXPERIMENTAL
Intervention: Clindamycin phosphate 1.2% and tretinoin 0.025% combination gel
Number of subjects: 79

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study: 20856131

Group type: EXPERIMENTAL
Intervention: Special intervention (education on physical activity)
Number of subjects: 501

Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 501
Study: 20071811

Group type: EXPERIMENTAL
Intervention: Lignocaine with adrenaline + 4 mg Dexamethasone (Group C)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Lignocaine with adrenaline + 500 microg Neostigmine (Group B)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Lignocaine with adrenaline (Group A)
Number of subjects: 90
Study: 16871922

Group type: EXPERIMENTAL
Intervention: Benzalkonium chloride (BKC) 0.01% in saline nasal spray
Number of subjects: 43

Group type: COMPARATOR
Intervention: Preservative-free saline
Number of subjects: 43
Study: 15596923

Group type: EXPERIMENTAL
Intervention: Stereotactic radiosurgery (SRS) eligible patients (RPA class 3)
Number of subjects: 509

Group type: EXPERIMENTAL
Intervention: Stereotactic radiosurgery (SRS) eligible patients (RPA class 4)
Number of subjects: 509

Group type: COMPARATOR
Intervention: Stereotactic radiosurgery (SRS) ineligible patients (RPA class 4)
Number of subjects: 509

Group type: EXPERIMENTAL
Intervention: Stereotactic radiosurgery (SRS) eligible patients (RPA class 5)
Number of subjects: 509

Group type: COMPARATOR
Intervention: Stereotactic radiosurgery (SRS) ineligible patients (RPA class 5)
Number of subjects: 509

Group type: EXPERIMENTAL
Intervention: Stereotactic radiosurgery (SRS) eligible patients (RPA class 6)
Number of subjects: 509

Group type: COMPARATOR
Intervention: Stereotactic radiosurgery (SRS) ineligible patients (RPA class 6)
Number of subjects: 509
Study: 11706096

Group type: EXPERIMENTAL
Intervention: Bupropion SR (150 mg daily for 1 week, then 300 mg daily for 5 weeks)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 9282701

Group type: EXPERIMENTAL
Intervention: Group 1 (prescription and verbal instructions)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Group 2 (prescription, syringe, and demonstration)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Group 3 (prescription, syringe with marked line, and demonstration)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Follow-up demonstration
Number of subjects: 90
Study: 7942479

Group type: EXPERIMENTAL
Intervention: Amiodarone treatment for 3 to 6 months (n = 11)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Amiodarone treatment for > 1 year (n = 13)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Baseline (n = 10)
Number of subjects: 34
Study: 3662543

Group type: EXPERIMENTAL
Intervention: Sodium thiosulfate (STS)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Cis-dichlorodiammineplatinum (CDDP) alone
Number of subjects: 45
Study: 31155682

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) for 12 weeks
Number of subjects: 178

Group type: COMPARATOR
Intervention: PFMT-solifenacin for 36 weeks
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 178

Group type: COMPARATOR
Intervention: PFMT-solifenacin
Number of subjects: 178
Study: 30159716

Group type: EXPERIMENTAL
Intervention: Ranked feedback
Number of subjects: 7846

Group type: COMPARATOR
Intervention: Control (no feedback)
Number of subjects: 7846

Group type: EXPERIMENTAL
Intervention: Benchmarked feedback
Number of subjects: 7846

Group type: COMPARATOR
Intervention: Control vs Benchmarked
Number of subjects: 7846

Group type: COMPARATOR
Intervention: Control vs Ranked
Number of subjects: 7846
Study: 26918891

Group type: EXPERIMENTAL
Intervention: S. mansoni
Number of subjects: 2316

Group type: EXPERIMENTAL
Intervention: T. trichiura
Number of subjects: 2316

Group type: EXPERIMENTAL
Intervention: M. perstans
Number of subjects: 2316

Group type: EXPERIMENTAL
Intervention: A. lumbricoides
Number of subjects: 2316
Study: 25392260

Group type: EXPERIMENTAL
Intervention: Maximal exercise protocol
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Critical difference for sal‐T
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Critical difference for sal‐C
Number of subjects: 35
Study: 23547078

Group type: EXPERIMENTAL
Intervention: Rituximab purging (P+; 375 mg/m(2) once per week for 4 weeks)
Number of subjects: 280

Group type: COMPARATOR
Intervention: Observation (NP) before HDC-ASCT
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Maintenance rituximab (M+; 375 mg/m(2) once every 2 months for four infusions)
Number of subjects: 280

Group type: COMPARATOR
Intervention: Observation (NM)
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Rituximab purging (P+)
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Rituximab maintenance (M+)
Number of subjects: 280
Study: 20952020

Group type: EXPERIMENTAL
Intervention: Degarelix
Number of subjects: 100

Group type: COMPARATOR
Intervention: Leuprolide
Number of subjects: 100
Study: 18171718

Group type: EXPERIMENTAL
Intervention: Community based occupational therapy (10 sessions over five weeks)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Community based occupational therapy
Number of subjects: 135

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 135
Study: 17148797

Group type: COMPARATOR
Intervention: General anaesthesia followed by postoperative intravenous patient‐controlled analgesia with morphine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Combined spinal‐epidural anaesthesia followed by postoperative epidural infusion of bupivacaine 0.1% with fentanyl 2 microg/mL
Number of subjects: 60
Study: 15272949

Group type: EXPERIMENTAL
Intervention: High power group with illegitimate power hierarchy
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Low power group with illegitimate power hierarchy
Number of subjects: 230

Group type: COMPARATOR
Intervention: High power group with legitimate power hierarchy
Number of subjects: 230

Group type: COMPARATOR
Intervention: Low power group with legitimate power hierarchy
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Groups within an unfair power hierarchy
Number of subjects: 230

Group type: COMPARATOR
Intervention: Groups with legitimately high or low power
Number of subjects: 230
Study: 10743873

Group type: EXPERIMENTAL
Intervention: High anger feedback
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dishonesty feedback
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anger induction (insulted participants)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Verbalizing emotions about being insulted
Number of subjects: 0
Study: 8785144

Group type: EXPERIMENTAL
Intervention: Tramadol 200 mg i.v.
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Tramadol 100 mg i.v.
Number of subjects: 51

Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 51
Study: 1488688

Group type: EXPERIMENTAL
Intervention: Mefloquine (4 tablets, 1000 mg) plus tetracycline (250 mg qid for 7 days)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: MSP (4 tablets, one tablet contains 250 mg mefloquine, 500 mg sulfadoxine and 25 mg pyrimethamine) plus tetracycline (250 mg qid for 7 days)
Number of subjects: 51
Study: 3698068

Group type: EXPERIMENTAL
Intervention: 750-ml spacer
Number of subjects: 40

Group type: COMPARATOR
Intervention: ordinary MDI
Number of subjects: 40
Study: 31663986

Group type: EXPERIMENTAL
Intervention: 12-week resistance band exercise training (EX, n=10)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (CON, n=10)
Number of subjects: 20
Study: 29767326

Group type: EXPERIMENTAL
Intervention: Fluorescence-supported extended pelvic lymph node dissection (ICG-ePLND)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Regular extended pelvic lymph node dissection (ePLND)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: ICG-ePLND
Number of subjects: 120

Group type: COMPARATOR
Intervention: Regular ePLND
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 120
Study: 27586072

Group type: EXPERIMENTAL
Intervention: STP-PreK Enhanced
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: STP-PreK
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: SRPP
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (standard behavioral modification system and academic curriculum)
Number of subjects: 45
Study: 23932140

Group type: EXPERIMENTAL
Intervention: Nebulized heparin sulfate 10,000 IU
Number of subjects: 29

Group type: COMPARATOR
Intervention: Nebulized heparin sulfate 5,000 IU
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control (N-acetylcysteine)
Number of subjects: 29
Study: 22452973

Group type: COMPARATOR
Intervention: Arm endurance training
Number of subjects: 52

Group type: COMPARATOR
Intervention: Combined arm endurance and strength training
Number of subjects: 52

Group type: COMPARATOR
Intervention: Arm strength training
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: No arm training (control group)
Number of subjects: 52
Study: 20139111

Group type: EXPERIMENTAL
Intervention: naïve simulator
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: coached simulator
Number of subjects: 82

Group type: COMPARATOR
Intervention: control
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: average to peak force ratio
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Word Memory Test (WMT)
Number of subjects: 82
Study: 18332450

Group type: EXPERIMENTAL
Intervention: IV iron sucrose (200 mg iron) once per week for 4 weeks then once every other week for a further 4 weeks
Number of subjects: 46

Group type: COMPARATOR
Intervention: Oral ferrous succinate, 200 mg three times per day for 8 weeks
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: IV iron sucrose
Number of subjects: 46
Study: 15757578

Group type: EXPERIMENTAL
Intervention: Verbalizing groups
Number of subjects: 48

Group type: COMPARATOR
Intervention: Nonverbalizing groups
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Groups with 1-2 player replacements
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Groups with 3 player replacements
Number of subjects: 48
Study: 12602671

Group type: EXPERIMENTAL
Intervention: Pari Inhalierboy (2 mg budesonide)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Pari LC Jet Plus (2 mg budesonide)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Maxin MA-2 (2 mg budesonide)
Number of subjects: 12

Group type: COMPARATOR
Intervention: 4 mg budesonide orally
Number of subjects: 12

Group type: COMPARATOR
Intervention: 0.5 mg budesonide intravenously
Number of subjects: 12
Study: 10584978

Group type: EXPERIMENTAL
Intervention: Fusidic acid 500 mg/day for 28 days (group B)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Fusidic acid 500 mg/day for 14 days (group A)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (group C)
Number of subjects: 30
Study: 8947990

Group type: EXPERIMENTAL
Intervention: Coumatrak method for INR determination
Number of subjects: 32

Group type: COMPARATOR
Intervention: Conventional laboratory method for INR determination
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Pharmacist intervention in managing warfarin therapy
Number of subjects: 32
Study: 1835223

Group type: EXPERIMENTAL
Intervention: Intravenous teicoplanin
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Intramuscular teicoplanin
Number of subjects: 75
Study: 7195047

Group type: EXPERIMENTAL
Intervention: First breast
Number of subjects: 24

Group type: COMPARATOR
Intervention: Second breast
Number of subjects: 24

Group type: COMPARATOR
Intervention: Second breast (while feeding from the first)
Number of subjects: 24
Study: 30844804

Group type: EXPERIMENTAL
Intervention: Physical Activity (PA)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Sedentary (SED)
Number of subjects: 50
Study: 28977574

Group type: EXPERIMENTAL
Intervention: 6 hours/night time-in-bed (short sleep)
Number of subjects: 30

Group type: COMPARATOR
Intervention: 9 hours/night time-in-bed (long sleep)
Number of subjects: 30
Study: 25733629

Group type: EXPERIMENTAL
Intervention: CFR intervention (optimized complementary feeding recommendations)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: CFR group
Number of subjects: 240
Study: 24732048

Group type: EXPERIMENTAL
Intervention: Opportunity to take part in the trial (opt-in)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Opportunity to be removed from the trial (opt-out)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Choice to have standard treatment or take part in the trial (choice)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Full information in patient decision aid format
Number of subjects: 124
Study: 22168274

Group type: EXPERIMENTAL
Intervention: Fludarabine alone
Number of subjects: 777

Group type: EXPERIMENTAL
Intervention: Fludarabine with cyclophosphamide (FC)
Number of subjects: 777

Group type: COMPARATOR
Intervention: Chlorambucil
Number of subjects: 777

Group type: EXPERIMENTAL
Intervention: Sustained remissions
Number of subjects: 777

Group type: EXPERIMENTAL
Intervention: Disease progression
Number of subjects: 777
Study: 19719498

Group type: EXPERIMENTAL
Intervention: Right atrial appendage (RAA) stimulation
Number of subjects: 25

Group type: COMPARATOR
Intervention: Bachmann's Bundle (BB) stimulation
Number of subjects: 25
Study: 17889679

Group type: EXPERIMENTAL
Intervention: One-visit treatment
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Two-visit treatment
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Negative microbiologic sample
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Positive microbiologic sample
Number of subjects: 101

Group type: COMPARATOR
Intervention: Comparison between one-visit and two-visit treatments
Number of subjects: 101
Study: 15209452

Group type: EXPERIMENTAL
Intervention: Manipulation, exercise, and physician consultation
Number of subjects: 204

Group type: COMPARATOR
Intervention: Consultation alone
Number of subjects: 204
Study: 12218286

Group type: EXPERIMENTAL
Intervention: Dithranol ointment (2%) once daily for 30 min + vehicle of calcipotriol (50 microg/g) twice daily
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Dithranol ointment (2%) once daily for 30 min + calcipotriol (50 microg/g) twice daily
Number of subjects: 46
Study: 10972606

Group type: EXPERIMENTAL
Intervention: Propofol-ketamine
Number of subjects: 78

Group type: COMPARATOR
Intervention: Fentanyl-enflurane (controls)
Number of subjects: 78
Study: 8641492

Group type: EXPERIMENTAL
Intervention: Daily hMG beginning on cycle day 3 (Group A)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Combination of CC days 3 through 7 followed by hMG from day 7 onward (Group B)
Number of subjects: 0
Study: 1295525

Group type: EXPERIMENTAL
Intervention: Topical dexamethasone 0.1% (Maxidex)
Number of subjects: 184

Group type: COMPARATOR
Intervention: Topical fluorometholone 0.1% (FML Liquifilm)
Number of subjects: 184

Group type: COMPARATOR
Intervention: Topical naphazoline hydrochloride 0.1% (Albalon)
Number of subjects: 184

Group type: COMPARATOR
Intervention: Combined treatments (FML and Albalon)
Number of subjects: 184
Study: 6470194

Group type: EXPERIMENTAL
Intervention: Thioridazine tablets
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thioridazine suspension
Number of subjects: 0

Group type: COMPARATOR
Intervention: Thioridazine tablets and suspension (comparison)
Number of subjects: 0
Study: 31210092

Group type: EXPERIMENTAL
Intervention: Intensive residential rehabilitation
Number of subjects: 256

Group type: COMPARATOR
Intervention: Residential supported living
Number of subjects: 256
Study: 29381827

Group type: EXPERIMENTAL
Intervention: Nutrition and hygiene education intervention
Number of subjects: 399

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 399
Study: 26845375

Group type: EXPERIMENTAL
Intervention: High-reinforcement (HR) condition
Number of subjects: 403

Group type: COMPARATOR
Intervention: Low-reinforcement (LR) condition
Number of subjects: 403

Group type: EXPERIMENTAL
Intervention: Program completers
Number of subjects: 403

Group type: COMPARATOR
Intervention: Non-completers
Number of subjects: 403
Study: 24885032

Group type: EXPERIMENTAL
Intervention: Home jejunostomy feeding for six weeks after discharge
Number of subjects: 60

Group type: COMPARATOR
Intervention: Treatment-as-usual (control)
Number of subjects: 60
Study: 22525206

Group type: EXPERIMENTAL
Intervention: Metformin (500 mg once per day)
Number of subjects: 360

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 360
Study: 20581787

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 1200 mg/day for 8 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 18346881

Group type: EXPERIMENTAL
Intervention: DHEA (100 mg/day)
Number of subjects: 49
Study: 16249219

Group type: EXPERIMENTAL
Intervention: Abciximab plus stenting
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo plus stenting
Number of subjects: 300
Study: 14530158

Group type: EXPERIMENTAL
Intervention: Altered fractionation schemes based on different radiobiological mechanisms; specific dosage and duration not available.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Retrospective clinical data analysis; specific intervention details not available.
Number of subjects: 0
Study: 10487657

Group type: EXPERIMENTAL
Intervention: HRT (transdermal 17beta‐estradiol, 50 microg/day; plus oral norethisterone acetate, 1 mg/day)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: MFP (oral monofluorophosphate, 20 mg/day)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: HRT+MFP
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 8765440

Group type: EXPERIMENTAL
Intervention: 7-day continuous etoposide infusion at doses from 30 to 75 mg/m2 per day (schedule A)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: 21-day continuous etoposide infusion at doses from 18 to 40 mg/m2 per day (schedule B)
Number of subjects: 54
Study: 1837047

Group type: EXPERIMENTAL
Intervention: Manual therapy
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Physiotherapy
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Continued treatment by the general practitioner
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 300